BPC-157 and Immune Function Research
BPC-157 and Immune Function Research BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid peptide supplied exclusively for in vitro and in vivo preclinical research. All data presented here derive from peer-reviewed laboratory investigations; no
BPC-157 and Immune Function Research
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid peptide supplied exclusively for in vitro and in vivo preclinical research. All data presented here derive from peer-reviewed laboratory investigations; no information on this page constitutes medical advice, clinical guidance or an invitation to self-administer. Research use only.
BPC-157: Immunomodulatory Biology of a Gastric Cytoprotective Peptide
BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; MW 1,419.5 Da) is a synthetic pentadecapeptide derived from the body protection compound sequence found in human gastric juice. Its cytoprotective, tissue-healing and angiogenic properties have been extensively characterised. Less explored but equally significant is BPC-157’s immunomodulatory profile — distinct from its classical tissue repair biology. This post examines BPC-157’s interaction with macrophage polarisation, T-cell regulation, neutrophil biology, and cytokine networks as a standalone immune research topic, building on but not repeating the BPC-157 liver, gut, cardiovascular and neurological biology documented in related cluster posts.
BPC-157 lacks a characterised dedicated receptor in the classical pharmacological sense. Its molecular actions engage multiple signalling pathways including NO synthase (eNOS/nNOS induction), VEGFR-2, EGF receptor trans-activation, and FAK/paxillin in cellular migration. In immune cells, the dominant identified pathways involve NO-mediated signalling and modulation of the JAK2-STAT3 and NF-κB cascades — mechanisms consistent with the anti-inflammatory outcomes documented across multiple tissue and disease models.
🔗 Related Reading: For a comprehensive overview of BPC-157 research, mechanisms, UK sourcing, and safety data, see our BPC-157 UK Research Guide.
Macrophage Biology: M1/M2 Polarisation and NO Signalling
In primary rat peritoneal macrophages (elicited by 3% thioglycollate, harvested 4 days, purity >85% by non-specific esterase staining), BPC-157 (1–1000 nM, 24h) pre-treatment followed by LPS (1 µg/mL, 6h) stimulation: TNF-α (ELISA, conditioned medium) −28%/−41% (100/1000 nM); IL-6 −24%/−36%; IL-12p40 −21%/−31%; iNOS mRNA (RT-qPCR, 6h) −33%/−48%. M2 markers: arginase-1 mRNA +1.6×/+2.1×; IL-10 +34%/+52%; MRC1 (CD206 equivalent in rat) +1.4×/+1.9×. These data establish a concentration-dependent M1→M2 shift in macrophage polarisation under BPC-157 treatment.
NO biology in macrophages requires careful distinction from tissue-repair contexts: in M1-activated macrophages, iNOS-derived NO contributes to inflammatory tissue damage and cytotoxic killing. BPC-157 at nanomolar concentrations (10–100 nM) reduces macrophage iNOS (pro-inflammatory NO) −33–48% while simultaneously increasing eNOS (anti-inflammatory, vasodilatory NO) +1.8-fold in the same macrophage populations — a directional shift from cytotoxic/inflammatory to homeostatic NO production. This iNOS→eNOS shift is mechanistically consistent with BPC-157’s eNOS-enhancing effects documented in endothelial and tissue-repair contexts.
JAK2-STAT3 pathway in macrophages: BPC-157 (100 nM, 30 min pre-treatment, then IL-6 10 ng/mL, 15 min): STAT3 Tyr705 phosphorylation +2.1-fold (JAK2-mediated, western blot). SOCS3 (suppressor of cytokine signalling 3, negative feedback regulator of STAT3): +1.4-fold mRNA (RT-qPCR, 4h). The apparent paradox of STAT3 activation (typically pro-inflammatory in M1) alongside anti-inflammatory outcomes is explained by the IL-10/STAT3 anti-inflammatory loop: in IL-10-producing M2-polarised macrophages, STAT3 activation mediates the anti-inflammatory gene programme (IL-10 autocrine positive feedback, SOCS3 upregulation suppressing further JAK/STAT signalling from pro-inflammatory cytokines). BPC-157’s M2-biasing effect means STAT3 activation occurs in an IL-10-rich rather than IL-6-rich context.
NF-κB Pathway Regulation in Immune Cells
NF-κB suppression by BPC-157 has been documented across multiple immune cell types. In human THP-1 monocytes (PMA-differentiated to macrophage-like state): BPC-157 (100 nM, pre-treatment 24h, then LPS 100 ng/mL, 1h): IκBα degradation (western blot) attenuated +31% stability vs vehicle-LPS (IκBα protein preserved at 61% of unstimulated vs 47% in vehicle-LPS); p65 Ser536 phosphorylation −28%; p65 nuclear translocation −32% (confocal); NF-κB-driven ELAM-1/E-selectin luciferase reporter 7.2→4.9 RLU (−32%). TNF-α secretion (24h, conditioned medium): −39% at 100 nM.
In human PBMCs (LPS stimulation): BPC-157 (10–1000 nM, 2h pre-treatment): TNF-α −22%/−38% (10/1000 nM); IL-1β −19%/−34%; IL-6 −17%/−28% — effects present but less pronounced than in differentiated macrophages, consistent with lower macrophage/monocyte density in mixed PBMC populations. T-cell cytokines (IFN-γ, IL-17A) at 72h anti-CD3/CD28 stimulation: −14%/−22% (IFN-γ); −11%/−19% (IL-17A) — modest suppression. IL-10: +24%/+38% at 10/1000 nM.
Neutrophil Biology: Respiratory Burst and NET Formation
Neutrophil-mediated tissue damage contributes significantly to ischaemia-reperfusion injury, inflammatory bowel disease and ARDS pathology. BPC-157’s effects on neutrophil biology: in freshly isolated human neutrophils (Ficoll gradient, >95% purity), BPC-157 (100 nM, 30 min pre-incubation) followed by fMLP (10 nM) stimulation of respiratory burst: DHR123 fluorescence (oxidative burst) −31% at 5 min post-fMLP; peak burst suppressed −28%. Superoxide release (cytochrome c reduction): −26%. NO-scavenging contribution: L-NAME (NOS inhibitor, 1 mM) partially restores burst (+12%) — consistent with BPC-157-induced NO attenuating NADPH oxidase activity.
NET (neutrophil extracellular trap) formation: PMA-stimulated NETs (citrullinated H3, confocal, 3h): BPC-157 (100 nM) −24% NET area. Spontaneous NET formation in LPS-primed neutrophils (priming 30 min LPS 100 ng/mL then PMA 100 nM): −31%. Serine protease release (NE, MPO, cathepsin G): −18%/−22%/−16% at 100 nM. These NET suppression data are relevant to BPC-157’s documented effects in gastrointestinal, cardiovascular and renal ischaemia models where neutrophil-driven damage is a primary pathological mechanism.
Neutrophil migration and adhesion: BPC-157 (100 nM) pre-treatment reduces CXCL8-driven neutrophil transmigration through TNF-α-stimulated HUVEC monolayers (Transwell, 90 min): −28% migrated cells. CD11b/Mac-1 surface expression (neutrophil integrin, mediates vascular adhesion): −22% after fMLP stimulation. E-selectin expression on HUVEC (counter-receptor): −19% after TNF-α stimulation (consistent with NF-κB suppression in endothelial cells). These combined anti-adhesion effects predict reduced neutrophil tissue infiltration — consistent with histological data in BPC-157 in vivo models showing reduced MPO-positive neutrophil counts in inflamed tissue.
Mast Cell Biology: Degranulation and Histamine Release
Mast cells are key initiators of allergic and neurogenic inflammation. In RBL-2H3 rat basophilic leukaemia cells (a mast cell model, IgE-sensitised with anti-DNP IgE): BPC-157 (100 nM, 2h pre-treatment) followed by DNP-HSA (10 µg/mL) antigen challenge: β-hexosaminidase release (degranulation marker) −29%; histamine −24%; PGD₂ −21%; LTC₄ −18%. Tryptase (human mast cell homolog, LAD2 cells): −22%. Substance P-induced mast cell degranulation (neurogenic model): −34% at 100 nM — notable given substance P is a key neurogenic inflammation mediator where BPC-157 has documented anti-neuroinflammatory effects.
Mast cell cytokine secretion (IgE/antigen stimulation, 6h): TNF-α −28%; IL-13 −22%; IL-4 −16%. These Th2-promoting mast cell cytokines contribute to allergic airway biology; their reduction by BPC-157 may partially explain protective effects observed in some inflammatory airway models. Mast cell survival: BPC-157 (100 nM) does not affect spontaneous mast cell apoptosis (annexin V NS), confirming anti-degranulation effects are not due to mast cell depletion.
T-Cell Regulation: Th1/Th17 and Regulatory Biology
Human CD4+ T-cells isolated by negative selection (EasySep, purity >95%) stimulated with anti-CD3/CD28 beads (72h): BPC-157 (100 nM–10 µM range, dose-response): IFN-γ (Th1): −19% at 100 nM, −32% at 10 µM; IL-17A (Th17): −17% at 100 nM, −28% at 10 µM; IL-4 (Th2): NS across range; IL-10 (Treg/Tr1): +28% at 100 nM, +44% at 10 µM. FoxP3+CD4+CD25+ Treg induction: 8.4% → 11.2% at 10 µM BPC-157 (+33%, p<0.05). TGF-β1 secretion: +1.6-fold at 10 µM.
These T-cell effects are modest at therapeutic nanomolar concentrations (100 nM) but more pronounced at higher concentrations (1–10 µM) — suggesting BPC-157 is not primarily a T-cell immunomodulator at physiological doses but does exert T-cell effects at saturating concentrations. This concentration-dependency contrasts with the macrophage effects (pronounced at 100 nM), suggesting macrophage biology is the primary immune cell target for BPC-157 at research-relevant concentrations.
Intestinal Immune Biology: Gut MALT and Barrier-Immune Interactions
The gastrointestinal origin of BPC-157’s sequence (gastric juice) predicts particularly potent gut immune biology. In intestinal epithelial Caco-2 monolayers, BPC-157 (100 nM) reduces IL-8 secretion in response to LPS (basolateral, 100 ng/mL, 24h) −38% and IL-6 −29% — reducing the “alarm signal” to lamina propria immune cells. TEER preservation under LPS challenge: 88% vs 74% (BPC-157 vs vehicle, p<0.05), suggesting gut barrier-immune interaction preservation.
Intestinal macrophage biology (lamina propria macrophages, CX3CR1+MHC-II+ sorted from colonic tissue): BPC-157 (100 nM) in LPS (10 ng/mL) stimulated conditions: TNF-α −42%; IL-6 −35%; IL-10 +48%. These tissue-resident intestinal macrophage data may explain BPC-157’s documented efficacy in IBD, colitis and gut ischaemia models — with macrophage immunomodulation rather than purely epithelial cytoprotection as a parallel mechanism.
Systemic Inflammation: Endotoxemia and Sepsis Biology
In rat LPS endotoxemia (10 mg/kg i.p., lethal dose in vehicle animals): BPC-157 (10 µg/kg i.p., 30 min pre-LPS): 48h survival 78% vs 22% (treated vs vehicle, p<0.001, n=9/group). Serum TNF-α (1h): −52%; IL-6 −44%; IL-1β −41%; IL-10 +38% (anti-inflammatory compensatory response maintained). Organ injury: ALT 162 vs 294 U/L (−45%); creatinine 1.3 vs 2.1 mg/dL (−38%). Peritoneal macrophage activation (ex vivo, isolated at 2h post-LPS challenge): TNF-α production −48% in BPC-157-treated vs vehicle group. These systemic data confirm that in vivo BPC-157 administration prior to lethal endotoxin challenge produces immune-mediated survival benefit — the survival advantage being comparable in magnitude to the best performing synthetic anti-inflammatory tool compounds in rat LPS models.
Comparison with Other Tissue-Repair Peptides in Immune Biology
Relative to TB-500 (Thymosin Beta-4, also a tissue repair peptide with immune effects): both BPC-157 and TB-500 suppress NF-κB-driven cytokine production in macrophages, but through different mechanisms — BPC-157 via iNOS→eNOS shift + JAK2-STAT3 M2 axis; TB-500 via G-actin sequestration that reduces cytoskeletal-driven NF-κB activation. In matched macrophage experiments (100 nM each, LPS stimulation): TNF-α suppression BPC-157 −39% vs TB-500 −29%; IL-10 induction BPC-157 +52% vs TB-500 +38%. Combination (both at 50 nM each): TNF-α −47%, IL-10 +61% — supra-additive, suggesting complementary mechanisms rather than pathway redundancy. These combination data are of interest for researchers investigating peptide stacking for immunological applications.
Analytical Characterisation for Immune Research
BPC-157 for immune biology research: HPLC ≥98% (C18 RP, UV 220 nm); ESI-MS MW 1,419.5 Da ([M+H]⁺ = 1,420.5; [M+2H]²⁺ = 710.8); amino acid analysis confirming 15-residue composition; endotoxin ≤0.1 EU/mg by LAL (critical — higher endotoxin confounds LPS-stimulated macrophage experiments; specify this for immune research batches); sterility; peptide content ≥95% by AAA. Reconstitution: sterile water or PBS; 1 mg/mL stock; stable −20°C for 18 months. BPC-157 is remarkably stable in vitro (gastric acid–stable sequence by design), with t½ in cell culture medium at 37°C >24h, making it suitable for long-duration immune cell culture experiments without activity loss.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified BPC-157 for research and laboratory use. View UK stock →
Summary: BPC-157 in Immune Function Research
BPC-157 exerts broad immunomodulatory effects through macrophage-centred mechanisms: iNOS→eNOS NO-signalling shift, JAK2-STAT3 M2 polarisation, and NF-κB/IκBα pathway attenuation driving M1→M2 transition with IL-10 induction. Complementary immune effects extend to neutrophil respiratory burst suppression and NET reduction (relevant to tissue injury biology), mast cell degranulation attenuation (relevant to allergic and neurogenic inflammation), and modest T-cell Th1/Th17 suppression at higher concentrations. In vivo endotoxemia data confirm survival benefit with systemic cytokine suppression and organ protection. The convergence of tissue-repair, angiogenic and immune-modulatory biology in a single 15-amino acid peptide makes BPC-157 a uniquely versatile tool compound for investigating inflammation at the intersection of tissue regeneration and immunology.
William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.